Japan's Astellas is in trouble with the U.K.'s Prescription Medicines Code of Practice Authority after a whistleblower pointed out to authorities that the company may have been misleading when it said it had not purposely targeted oncologists during a meeting discussing the use of cancer drug Xtandi. New emails have led the group to look again at the matter. Report